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RESEARCH ARTICLE
N-[11C]Methyl-AMD3465 PET as a Tool for In
Vivo Measurement of Chemokine Receptor 4
(CXCR4) Occupancy by Therapeutic Drugs
S. V. Hartimath, M. A. Khayum, A. van Waarde, R. A. J. O. Dierckx, E. F. J. de Vries
Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1,
P.O. Box 31.0019713 GZ, Groningen, The Netherlands
Abstract
Purpose: Chemokine receptor 4 (CXCR4) is overexpressed in many cancers and a potential drug
target. We have recently developed the tracer N-[11C]methyl-AMD3465 for imaging of CXCR4
expression by positron emission tomography (PET). We investigated the pharmacokinetics of N-
[11C]methyl-AMD3465 in rats bearing a C6 tumor and assessed whether the CXCR4 occupancy by
the drug Plerixafor® can be measured with this PET tracer.
Procedure: A subcutaneous C6 tumor was grown in Wistar rats. Dynamic N-[11C]methyl-AMD3465
PET scanswith arterial blood samplingwas performed in control rats and rats pretreatedwith Plerixafor®
(30mg/kg, s.c). The distribution volume (VT) of the tracer was estimated by compartmentmodelingwith a
two-tissue reversible compartment model (2TRCM) and by Logan graphical analysis. The non-
displaceable binding potential (BPND)was estimatedwith the 2TRCM.Next, CXCR4 receptor occupancy
of different doses of the drug Plerixafor® (0.5–60 mg/kg) was investigated.
Results: The tumor could be clearly visualized by PET in control animals. Pretreatment with 30 mg/
kg Plerixafor® significantly reduced tumor uptake (SUV 0.65 ± 0.08 vs. 0.20 ± 0.01, p G 0.05). N-
[11C]Methyl-AMD3465was slowlymetabolized in vivo, with 70 ± 7%of the tracer in plasma still being
intact after 60 min. The tracer showed reversible in vivo binding to its receptor. Both 2TRCM
modeling and Logan graphical analysis could be used to estimate VT. Pre-treatment with 30 mg/kg
Plerixafor® resulted in a significant reduction inVT (2TCRM0.87 ± 0.10 vs. 0.23 ± 0.12, p G 0.05) and
BPND (1.85 ± 0.14 vs. 0.87 ± 0.12, p G 0.01). Receptor occupancy by Plerixafor® was dose-
dependent with an in vivo ED50 of 12.7 ± 4.0 mg/kg. Logan analysis gave comparable results.
Conclusion: N-[11C]Methyl-AMD3465 PET can be used to visualize CXCR4 expression and to
calculate receptor occupancy. VT determined by Logan graphical analysis is a suitable
parameter to assess CXCR4 receptor occupancy. This approach can easily be translated to
humans and used for early drug development and optimization of drug dosing schedules.
Key Words: Pet, Logan graphical analysis, Compartment modeling, Receptor occupancy,
CXCR4 receptors imaging
Introduction
Chemokine receptor 4 (CXCR4) is a member of the α-
chemokine receptor family, which is involved in maintaining
body homeostasis, hematopoiesis, immune cell trafficking,
and homing and retention of stem cells [1, 2]. However,
CXCR4 and its natural ligand stromal derived factor-1α
(CXCL12) also play a crucial role in the development,
proliferation, and metastasis of cancer [3]. Elevated expres-
sion of CXCR4 has been observed in more than 20 differentCorrespondence to: E. Vries; e-mail: e.f.j.de.vries@umcg.nl
human tumor types [4–6], and the level of CXCR4
expression was associated with tumor grade and poor
prognosis [7, 8]. CXCR4 has been considered as a target
for (adjuvant) cancer therapy [9, 10]. Inhibition of CXCR4-
mediated signaling has therapeutic efficacy by itself, but can
also have a synergistic effect with other anti-cancer drugs,
such as bortezomib, melphalan, doxorubicin, and dexameth-
asone [11].
In drug development, it is essential to know the kinetics
and the in vivo binding properties of a drug to its target at an
early stage, preferably in animal studies or in early clinical
trials. Usually, there is a threshold for the percentage of the
receptors that have to be occupied by the drug in order to
achieve a pharmacological effect. Currently, drug-dosing
regimens for patients are mainly based on the outcome of
preclinical and phase I-II studies. However, these studies
cannot elucidate the relationship between amount of drug
administered and the occupancy of the receptors in vivo.
Positron emission tomography (PET) can be used to
noninvasively measure receptor occupancy in vivo by
comparing the uptake of a specific tracer in the tissue of
interest before and after administration of one or more doses
of the drug under investigation. These studies can answer
many critical questions, such as whether the drug has
reached its target, the level of receptor occupancy after
administration of a therapeutic dose, and the duration of
receptor binding by the drug. With this information,
effective dosing regimens can be designed for the expensive
phase 3 clinical trials.
Recently, we have developed N-[11C]methyl-AMD3465
as a radiotracer for PET imaging of CXCR4 receptors [12].
The aim of this study is to investigate various methods for
quantification of CXCR4 availability using N-[11C]methyl-
AMD3465 PET in immune-competent tumor-bearing rats.
We also investigated whether this approach can be applied to
measure CXCR4 receptor occupancy of the drug
Plerixafor® (AMD3100 8HCl). To date, no report has been




All reagents and solvents were obtained from commercial
suppliers and used without further purification. AMD3100
octahydrochloride (Plerixafor®) was prepared as previously
described [13, 14]. A stock solution of Plerixafor® was
prepared in phosphate buffered saline (PBS) and neutralized
with 1 M NaOH. N-[11C]Methyl-AMD3465 was prepared as
previously described [12]. C6 rat glioma cells (ATCC,
Manassas, VA) were cultured in monolayers in Dulbecco’s
Modified Eagle Medium, supplemented with 10% fetal calf
serum. Cells were maintained in a humidified atmosphere
with 5% CO2 at 37 °C.
Animal Model
All animal experiments were performed in compliance with
the Dutch law on animal experiments. The protocol was
approved by the Institutional Animal Care and Use
Committee of the University of Groningen. Male Wistar
rats (n = 34, 300 ± 20 g, Harlan) were maintained at a 12-h
day and 12-h night regime and fed standard laboratory
chow ad libitum. Rat C6 glioma cells (3 million) in a
mixture of Matrigel and complete medium (1:1 (v/v)) were
subcutaneously injected into the right shoulder of the
animal. Solid tumors (350 ± 20 mg) were allowed to grow
for 5–6 days before the animals underwent PET
experiments.
The study was divided into two parts: first, different
pharmacokinetic modeling approaches to quantify N-
[11C]methyl-AMD3465 uptake were evaluated, then the
CXCR4 receptor occupancy of the drug Plerixafor was
investigated. Body weights and injected doses are shown in
Table 1.
Small Animal PET
Control animals (also used as baseline scan for occupancy
studies, n = 6) were anesthetized with a mixture of
isoflurane/air (5% induction and 2% maintenance, Teva
Pharmachemie, The Netherlands). A cannula was placed in
the femoral artery for rapid blood sampling, and another
cannula was inserted in the femoral vein for tracer injection.
Two animals were simultaneously place in the PET camera
(Focus-220, Siemens-Concorde). A transmission scan with a
Co-57-point source was made for attenuation and scatter
correction. After the transmission scan, 30 ± 5 MBq of N-
[11C]methyl-AMD3465 in a volume of 1 ml was injected.
The injection was performed with a syringe pump set at a
speed of 1 ml/min. The PET scan was started when the
tracer started to enter the body of the first animal. The
second animal was injected 16 min later. A 76-min list mode
protocol was used for data acquisition. A series of 15 blood
samples (0.10–0.15 ml) was drawn at 10, 20, 30, 40, 50, 60,
90, 120, 180, 300, 450, 600, 900, 1800, and 3600 s after
tracer injection. After a blood sample was taken, 0.15 ml of
heparinized saline was injected via the artery cannula to
prevent hypovolemia and large changes in blood pressure.
Radioactivity in 25 μl of plasma and 25 μl of whole blood
were determined and used as an arterial input function for
pharmacokinetic modeling.
To examine specific binding, six rats were pretreated with
Plerixafor® (30 mg/kg, s.c.), 30 min before the tracer
injection. Scanning was performed as described above. After
the scan, the animals were terminated under deep anesthesia.
List mode data of the emission scan was separated into 21
frames (6 × 10, 4 × 30, 2 × 60, 1 × 120, 1 × 180, 4 × 300,
3 × 600 s). Emission sinograms were iteratively recon-
structed (OSEM2D, 16 subsets, 4 iterations) after being
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normalized and corrected for attenuation, scatter, and
radioactive decay. The data sets consisted of 95 slices, with
a slice thickness of 0.8 mm and an in-plane 128 × 128 image
matrix with a pixel size of 1.1 mm. Images were smoothed
with a 1 mm Gaussian filter. Preliminary volumes of interest
(VOIs) were manually drawn around the tumor on the
summed PET images using the drawing tool of the software.
The final VOIs were generated automatically by the software
using 75% of the maximum uptake in the preliminary VOI
of the tumor as the threshold. For each VOI, a time activity
curve (TACs) was calculated using Inveon Research
Workplace software (Siemens-Concorde). Tracer uptake
was normalized to the injected tracer dose and body weight
and is presented as standardized uptake value (SUV). The
SUV values presented in this manuscript represent the
SUVmean within the 75% threshold ROI.
In Vivo Metabolite Analysis
For metabolite analysis, a group of rats (n = 6) were injected
with 50 ± 5 MBq of tracer while being anesthetized with a
mixture of isoflurane/air (5% induction and 2% mainte-
nance). A series of 0.5–0.8 ml arterial blood samples was
drawn at 5, 15, 30, 40, and 60 min after tracer injection.
Blood samples were centrifuged at 13,000 rpm for 2 min.
Plasma was collected, 0.1 mL of 70% H3PO4 was added,
and the solution was vortexed for 30 s. The mixture was
centrifuged for 2 min at 13,000 rpm, and the clear
supernatant was collected. The supernatant was analyzed
by HPLC (Shimadzu), using a μBondapak column
[7.8 × 300 mm, Waters] and water/acetonitrile (90/10 v/v)
as the eluent. The flow rate was set at 3 ml/min, and samples
were collected at time intervals of 30 s. The radioactivity in
the collected samples was measured with a gamma counter
(Compugamma CS1282, LKB-Wallac, Turku, Finland), and
the percentage of intact tracer was calculated. An average
metabolite curve was generated by fitting the data points of
all animals with an exponential function. Metabolite-
corrected plasma curves were generated by correcting the
plasma curves of the individual animals for the percentage of
intact tracer, using the population-based metabolite curve.
The metabolite-corrected plasma curves of individual
animals were used as an input function curve for pharma-
cokinetic modeling.
Compartment Modeling
Tracer kinetics of N-[11C]methyl-AMD3465 was analyzed
by compartmental modeling using the 1-tissue compartment
model (1TCM) and the 2-tissue reversible compartment
model (2TRCM). The whole blood curve and the
metabolite-corrected plasma curve were used as input
functions; the blood volume fraction (Vb) was not fixed.
Inveon workstation software (Siemens) was used to estimate
the model parameters (rate constants, Vb). Tracer uptake was
expressed as VT and non-displaceable binding potential
(BPND), which were defined as [15, 16].




Graphically, analysis was performed on the TACs of the
tumor, using the Logan and Gjedde–Patlak graphical
methods. The whole blood and the metabolite-corrected
plasma curves were used as input functions to calculate the
total volume of distribution (VT) in the tumor.
Receptor Occupancy
CXCR4 occupancy was investigated in C6 tumor-bearing
rats that were subcutaneously injected with different doses of
Plerixafor® (0.5, 3, 10, 30, and 60 mg/kg, n = 3/dose). After
30 min, N-[11C]methyl-AMD3465 was administered and a
60-min dynamic PET scan with arterial blood sampling was
performed as described above. Compartment modeling with
the 2TRCM and Logan graphical analysis were used to
determine the VT in the tumor. Scans from control animals
were used as baseline scans, because repetitive PET scans
with arterial blood sampling in the same animal was not
possible. The occupancy of the drug was calculated from the
average VT of control animals (VT (baseline)), the VT of
Table 1. Body weight and injected dose of the tracer. Animals were treated with saline or different doses of Plerixafor 30 min before tracer injection. Data
are reported as mean ± standard deviation
Group Plerixafor® dose Body weight Injected dose
Kinetic modeling study g MBq nmol
Control (n = 6) Saline 351 ± 31 30 ± 5 0.65 ± 0.12
Pretreated (n = 6) 30 mg/kg s.c 320 ± 25 36 ± 8 0.76 ± 0.20
Receptor occupancy study
Dose-1 (n = 3) 0.5 mg/kg. s.c 301 ± 16 32 ± 4 0.68 ± 0.06
Dose-2 (n = 3) 3.0 mg/kg. s.c 326 ± 20 35 ± 5 0.74 ± 0.10
Dose-3 (n = 3) 10 mg/kg. s.c 317 ± 19 38 ± 8 0.80 ± 0.19
Dose-4 (n = 3) 30 mg/kg. s.c 315 ± 15 31 ± 2 0.69 ± 0.05
Dose-5 (n = 3) 60 mg/kg. s.c 335 ± 13 34 ± 4 0.72 ± 0.08
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animals that were administered the drug (VT (drug)) and the
non-displaceable binding (VND). The VND was estimated by
extrapolating the fit of the VT versus drug dose curve to an
infinite drug dose.
The occupancy of Plerixafor® was estimated according to
the formula:
Occupancy ¼ V t baselineð Þ−V t drugð Þ½ 
V t baselineð Þ−VND
 
 100%
In addition, the drug occupancy was calculated using the
BPND, according to the formula:





All results are expressed as mean ± standard deviation.
Statistical analyses were performed using the two-sided
unpaired students’t test in GraphPad Prism 5. A probability
(p) value G0.05 was considered statistically significant.
Results
PET Imaging
The N-[11C]methyl-AMD3465 PET images (0–60 min) of a
control rat with a C6 tumor and a rat pretreated with 30 mg/
kg Plerixafor® are represented in Fig. 1. The C6 tumor is
clearly visible in the control animal, but not in the
Plerixafor® treated animal, indicating that the drug is able
to compete with the PET tracer for the binding site of
CXCR4. Pretreatment with 30 mg/kg Plerixafor®
significantly reduced the tracer uptake in the tumor (SUV
0.65 ± 0.08 vs. 0.20 ± 0.01, p G 0.05). Figure 1 shows that
pretreatment with the CXCR4 antagonist also reduces tracer
uptake in the salivary glands, which can be explained by the
relatively high expression levels of the CXCR4 receptors in
these glands [17].
Tracer Kinetics
Figure 2 presents the average TACs of N-[11C]methyl-
AMD3465 in the tumor of control and Plerixafor®
pretreated animals. Tracer uptake in the tumor reached a
maximum at 30 s after injection, followed by a bi-
exponential clearance in both groups. The clearance half-
lifes of the tracer from the tumor were 10 ± 1 min (10%) and
129 ± 9 min (90%) in control rats and 8 ± 3 min (14%) and
6 8 ± 5 min (86%) in Plerixafor®-treated animals.
Pretreatment with Plerixafor® resulted in significantly
(p G 0.05) lower activity levels in the tumor of pretreated
animals than in tumors of control animals beyond 5 min
after tracer injection (Fig. 2a). The clearance of the tracer
from plasma was not affected by the drug treatment
(Fig. 2b), as plasma activity was not significantly different
between control animals and Plerixafor® pretreated rats at
any time point.
Metabolite Analysis
HPLC analysis of plasma samples showed the formation of
one radioactive metabolite that was more hydrophilic than
N-[11C]methyl-AMD3465 (retention times: N-[11C]methyl-
AMD3465 8 min, radioactive metabolite 5 min; Fig. 3a).
The tracer was slowly metabolized in vivo, and metabolism
was highly reproducible between animals. The percentage of
intact tracer decreased from 98 ± 2% at 5 min to 70 ± 7% at
60 min (Fig. 3b).
Fig. 1. Coronal PET images (0–60 min) of C6 tumor-bearing Wistar rats.a Control animal (baseline) with the tumor and heart in
the field of view. b Animal pre-treated with AMD3100 8HCl (Plerixafor® 30 mg/kg), 30 min before the tracer injection. The arrow
indicates the position of the tumor; Sg Salivary gland, Ln Lymph node and Ht Heart.
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Compartment Modeling
TACs generated from the VOI of the tumor were analyzed
with two reversible compartment models: 1TCM and
2TRCM. The Akaike information criterion values (AIC)
values were 423 ± 28 and 296 ± 13 for the 1TCM and
2TRCM, respectively, indicating that tracer kinetics could be
better fitted with the 2TRCM. Therefore, the 2TRCM was
used to estimate the parameters K1, k2, k3, k4, and Vb,
which were subsequently converted into VT and BPND
(Table 2). Animals treated with 30 mg/kg s.c. Plerixafor®
showed a significantly lower BPND than control animals
(1.85 ± 0.14 vs. 0.87 ± 0.12, p G 0.01). Similarly, the VT was
significantly reduced after pretreatment with Plerixafor®
(79%, p G 0.05). Pretreatment with Plerixafor did not affect
the curve fit, as tracer kinetics could still be fitted by the
2TRCM. Compartment modeling with the 2TRCM indicated
that the estimated total blood volume (Vb) was not affected
by Plerixafor® treatment (0.07 ± 0.04 vs. 0.06 ± 0.03 in
control and drug-treated animals, respectively).
Graphical Analysis
Figure 4 shows representative examples of a Logan and a Patlak
plot of N-[11C]methyl-AMD3465 uptake in the tumor. The tracer
kinetics showed a better fit with Logan graphical analysis
(R2 = 0.99 ± 0.08) than with Patlak analysis (R2 = 0.47 ± 0.92),
confirming that the binding of N-[11C]methyl-AMD3465 to
CXCR4 receptors is reversible. The VT calculated by Logan
graphical analysis was significantly lower in rats pretreated with
30 mg/kg s.c. Plerixafor® than in control rats (0.18 ± 0.10 vs.
0.79 ± 0.16, p G 0.05), indicating that the tracer displays specific
binding to the CXCR4 receptor (Table 2).
Receptor Occupancy
In order to estimate drug occupancy from VT values at different
drug concentrations, first, the VND in tumor was calculated by
plotting the VT (dose) versus the drug concentration and
extrapolating the curve to infinite drug concentration (Fig. 5a).
The estimated VND determined from 2TRCM, and Logan derived
VT values was 0.088 ± 0.041 and 0.094 ± 0.034, respectively
(Table 3). Occupancy estimates based on VT values calculated
from 2TRCM analysis and Logan analysis gave comparable
results, and almost 100% occupancy was already obtained at
doses 930 mg/kg. In contrast, the occupancy calculated from the
BPND reached only 80% at the highest dose of 60 mg/kg (Fig. 5b,
Table 3). Occupancy determined from BPND values correlated
poorly with the occupancy calculated from VT values.
Fig. 2 a Time-activity curves of the C6 tumor in Wistar rats
(n = 6). Animals were either untreated (control) or injected
with 30 mg/kg Plerixafor® 30 min before the tracer injection
(pretreated). The uptake of the tracer is expressed as SUV
and corrected for injected dose, body weight and decay. b
Kinetics of N-[11C]methyl-AMD3465 in plasma. Plasma data
were corrected for the metabolites. Pre-treatment with
Plerixafor® did not significantly affect the kinetics of the
tracer in plasma. Error bars represent standard deviations.
Statistically significant differences are indicated by
* (p G 0.05).
Fig. 3. In vivo metabolite analysis (n = 6). a Chromatogram
representing the plasma metabolite analysis by HPLC. b
Graph showing the percentage of intact tracer in plasma as a
function of time. Error bars represent standard deviations.
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A non-linear regression analysis was used to estimate
the ED50 of Plerixafor® in the living animal. Thus, the
in vivo ED50 of the drug were 12.7 ± 4.0, 23.8 ± 4.2
and 14.2 ± 2.3 mg/kg when the occupancy was estimated
from the VT and BPND derived from 2TRCM, and VT
derived from Logan graphical analysis, respectively. The
non-linear regression of occupancy data derived from the
BPND did not reach a statistically significant curve fit
(p = 0.29.) and therefore the ED50 estimated by this
method should be considered as unreliable.
Discussion
In this study, we showed that occupancy of CXCR4
receptors by the drug Plerixafor® can be measured in vivo
in C6 glioma-bearing rats, using PET and kinetic modeling.
Plerixafor® is a potent and selective CXCR4 receptor
antagonist, which was originally developed as an anti-HIV
drug, but nowadays, it is also used as a drug in adjuvant
cancer therapy and to stimulate the mobilization of hemato-
poietic stem cells from bone marrow for autologous
transplantation. Using N-[11C]methyl-AMD3465 PET, we
assessed CXCR4 receptor occupancy by the drug and
calculated its ED50 in vivo.
Pretreatment with Plerixafor® (30 mg/kg) resulted in a
significant reduction in the uptake of the tracer in the
tumor, indicating that N-[11C]methyl-AMD3465 shows
specific binding to CXCR4 receptors. Tracer kinetics in
blood and plasma were not affected by pretreatment with
Table 2. Results of kinetic modeling of N-[11C]methyl-AMD3465 tumor kinetics in C6 glioma-bearing Wistar rats. Animals were either untreated (control)
or treated with 30 mg/kg Plerixafor® 30 min prior to tracer injection. Data are presented as a mean ± standard deviation
Parameter Control Plerixafor®






VT 0.87 ± 0.10 0.23 ± 0.12 p G 0.05 2TRCM
BP 1.85 ± 0.14 0.87 ± 0.12 p G 0.01
Vb 0.07 ± 0.04 0.06 ± 0.03 NS
Graphical analysis Logan
VT 0.79 ± 0.16 0.18 ± 0.10 p G 0.05
NS not significant
Fig. 4. Representative graphical analyses of tracer uptake in
the C6 tumor. a Logan graphical analysis using a 10-min
delay time. b Patlak graphical analysis with a delay time of
20 min.
Fig. 5. Receptor occupancy graphs. a The receptor occu-
pancy was estimated by non-linear regression analysis. The
tumor distribution volume (VT) derived from 2TRCM and
Logan was used to calculate the nonspecific volume of
distribution (VND) by extrapolating to an infinite drug dose. b
Estimation of the ED50 from the receptor occupancy.
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Plerixafor®. We used only population-based metabolite
correction (PBMC), as we only observed little variation
within the population (Fig. 3b). In vivo metabolite analysis
of plasma showed that the tracer was slowly metabolized
in vivo, as approximately 70% of N-[11C]methyl-
AMD3465 was still intact 1 h after tracer injection. Only
one polar radioactive metabolite was detected in plasma
(Fig. 3a). MetaPrint2D software (Cambridge) predicted that
this metabolite of N-[11C]methyl-AMD3465 was either
formed by dealkylation at an amine group in the cyclam
ring or hydroxylation of a secondary nitrogen atom in the
cyclam. Since the cyclam ring is involved in ligand
binding to the active site of the receptor, it seems unlikely
that the radioactive metabolite has significant affinity for
CXCR4 (data not shown).
A potential bias in our study is that we did not assess the
effect of the drug on tracer metabolism. Our previous study
and other studies described in the literature, however,
indicate that the drug Plerixafor® is not metabolized
in vivo and is excreted unchanged in the urine [18]. We
assumed therefore that Plerixafor® does not substantially
compete with the metabolic route of the tracer and
consequently, that pretreatment with Plerixafor® did not
have any significant effect on the rate of metabolism of N-
[11C]methyl-AMD3465. This assumption is supported by
the fact that the plasma kinetics of the tracer were not
affected by Plerixafor®.
Different compartmental models were used to fit the PET
data, and the best model fit was obtained for 2TRCM.
Pretreatment with the drug Plerixafor® resulted in a
significant decrease in BPND and VT, indicating that specific
tracer uptake could be inhibited by saturation of the CXCR4
receptor. Logan and Patlak graphical analysis of the TACs
obtained from the tumor could be better fitted by Logan than
Patlak analysis. This confirms that the binding of N-
[11C]methyl-AMD3465 to the CXCR4 receptors is revers-
ible. Furthermore, estimation of total blood volume (Vb) was
included in the analysis, since it can be affected by treatment
with drugs [19]. In this study, however, we did not find any
effect of Plerixafor® on tumor blood volume.
PET is a noninvasive imaging technique, which can
provide insight into the relationship between receptor
occupancy and drug efficacy, provided a suitable radioligand
is available [20]. In the second part of our study, the
feasibility of determining CXCR4 receptor occupancy by
Plerixafor® using N-[11C]methyl-AMD3465 PET was
assessed. For this purpose, both VT and BPND values
obtained from 2TRCM and Logan analysis were used to
estimate the CXCR4 receptor occupancy. For occupancy
measurements, a reliable fit with high reproducibility is
necessary. Our data showed that VT obtained from either
2TRCM analysis or from Logan analysis were highly
correlated and gave a similar estimation of receptor
occupancy. In contrast, VT showed only a moderate
correlation with BPND and occupancy values obtained from
the BPND could not be reliably fitted to calculate the ED50.
Theoretically, BP could give more accurate results, because
it only relies on the receptor binding parameters k3 and k4,
whereas VT can also be affected by tracer delivery and tissue
clearance. In theory, one would therefore expect that BPND
is the parameter of choice to calculate the receptor
occupancy, since it is independent of physiological param-
eters that could be affected by drug pretreatment, like blood
flow, perfusion, non-specific binding, etc. However, BPND
relies on the accurate estimation of the k3 and k4 values with
the 2TRCM. Since the 2TRCM requires simultaneous
estimation of five parameters (K1, k2, k3, k4 and Vb), curve
fitting may sometimes be difficult, and the estimated values
for k3 and/or k4 can be highly sensitive to noise, especially
when the number of available receptors is low, for example,
in case of high receptor occupancy. Logan graphical analysis
was a more stable modeling approach which can be used
even when the 2TRCM does not fit properly.
A potential limitation of this study is that the effect of
the endogenous ligand CXCL12 was not assessed.
However, the effect of changes in binding of CXCL12
to CXCR4 on occupancy calculations was probably
negligible, because all animals likely had comparable
CXCL12 levels, as they received the same treatment.
Another limitation is that the C6 tumors express both
CXCR4 and CXCR7 [21]. Both CXCL12 and Plerixafor®
can bind to both CXCR4 and to CXCR7 [22]. Since N-
[11C]methyl-AMD3465 may also have some affinity to
CXCR7, both CXCR4 and CXCR7 may have contributed
to the occupancy measured in this study. These issues
need to be further addressed in future studies.
Table 3. Percentage of receptor occupancy calculated from the volume of distribution (VT) and non-displaceable binding potential (BPND) obtained from
2TRCM and Logan graphical analysis. The C6 tumor-bearing Wistar rats were treated with different concentrations of Plerixafor 30 min before tracer
injection. All data are expressed as the mean ± standard deviation
Drug concentration (n = 3, mg/kg) Occupancy (%) (VT-2TRCM) Occupancy (%) (BPND-2TRCM) Occupancy (%) (VT-Logan)
0.5 5 ± 4 6 ± 3 2 ± 1
3 31 ± 3 10 ± 1 26 ± 4
10 50 ± 2 27 ± 5 46 ± 5
30 93 ± 7 59 ± 2 90 ± 2
60 98 ± 1 79 ± 1 99 ± 1
ED50 (mg/kg) 12.7 ± 4.0 23.8 ± 4.2 14.2 ± 2.3
VND 0.088 ± 0.041 N.A. 0.094 ± 0.034
N.A. not applicable
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Conclusion
We have demonstrated that N-[11C]methyl-AMD3465 can
be used to quantify CXCR4 receptor occupancy in tumors
with PET. Tracer kinetics can be easily quantified by
compartment modeling using the 2TRCM, which gives
comparable estimates of VT as Logan graphical analysis.
Estimation of the BPND from the 2TRCM appears to be
sensitive to noise. N-[11C]methyl-AMD3465 PET seems to
be a useful tool to establish the relationship between drug
dose and CXCR4 receptor occupancy in vivo. This
technique could easily be translated to applications in
humans, like patient-tailored, individualized therapy moni-
toring, and development of new drugs for CXCR4 receptors.
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